Genaxis

CEO Mikyeong Son runs the investment committee. She is also listed as the personal-information manager on the firm’s website, which is common in lean Korean Registered Accelerators where the managing director retains final sign-off on every term sheet. The firm does not name any additional investment partners or venture partners in its public materials.

It operates as an accelerator, not a blind-pool venture fund. Genaxis is structured as a private individual investment association that mentors startups before and after seed rounds. The firm maintains two portfolio buckets — an incubation track for pre-revenue teams and an investment track for companies that have reached the start-up stage. Both tracks focus exclusively on biotechnology and healthcare services.

Seed and start-up rounds only. The firm’s own materials state it invests at the earliest stages and then supports companies through education programs, regulatory guidance, and global scale-up partnerships. It does not participate in Series B or later-stage rounds based on its disclosure.

Everything outside biotechnology and healthcare services. Genaxis’s website, portfolio, and incubation rosters show no exposure to software, deep-tech hardware, consumer internet, or any other sector. The firm’s self-description as a bio-specialist is a binding constraint, not a preference.

The firm’s public materials do not describe a proprietary sourcing model. Given that Genaxis runs a single office in Seoul’s Gangnam district and participates in the government’s Registered Accelerator framework, most deal flow likely originates from Korean university labs, hospital research foundations, and the local bio-cluster around Seocho-gu. The firm does not disclose any international scouting offices or formal university partnerships.